small molecule glp-1 agonist Aleniglipron: An Oral, GLP-1R Fast-Follower from Structure Therapeutics Binding sites and design strategies
Description
A meta-analysis of studies does show that people who lose more weight (e.g
Liraglutide results in two placebo-controlled studies were similar with a systolic BP change of 5.6 mmHg (95% CI 5.8, 5.4) and diastolic BP change of 4.5 mmHg (95% CI 4.7, 4.3)
2004;287:R1190R1193
Patients lost to follow-up were managed using the available data up to the point of their last recorded visit
Figure 1 highlights the physiology of the incretin hormones after a meal and the mode of action of DPP-4 inhibitors (7)
These metabolites interact with L-cells in your intestinal lining, which are the cells responsible for producing GLP-1
